Exparel is a brand-name prescription medication used for postsurgical pain management. Reimbursement for Exparel typically depends on factors such as the patient's insurance plan, the specific surgical procedure, and the healthcare setting in which it is administered [1].
Does Medicare cover Exparel?
Medicare Part B generally covers drugs administered in a physician's office or outpatient hospital setting if they are medically necessary and deemed "durable medical equipment" or a "drug that is not usually self-administered." Exparel can fall under these categories when used for certain pain management indications. However, coverage specifics can vary based on individual Medicare plans and local coverage determinations [1].
How is Exparel billed in hospitals?
In hospital settings, Exparel is typically billed under the hospital's prospective payment system. For outpatient services, it may be billed using specific CPT codes that represent the administration of the drug and the procedure it's associated with. The facility fee associated with the administration in an operating room or procedure suite can also be a component of the billing [1].
What challenges exist with Exparel reimbursement?
Reimbursement challenges can arise due to Exparel's cost and its use as an "add-on" payment in some settings. Payers may scrutinize its use for specific procedures, requiring strong clinical documentation to support medical necessity. The shift towards value-based care models can also influence reimbursement decisions, emphasizing outcomes and cost-effectiveness [1].
When does Exparel patent expire?
DrugPatentWatch.com tracks patent information for medications. Understanding patent expiry is crucial for anticipating when generic or biosimilar versions might become available, potentially impacting pricing and market dynamics. Specific patent details for Exparel can be found on specialized patent tracking websites [2].